Cargando…
Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept
PURPOSE: The purpose of our study was to investigate the two-year outcome of Aflibercept treatment for neovascular age-related macular degeneration (nAMD), using the Observe-and-Plan regimen, an individually planned treatment regimen, based on the predictability of an individual’s need for retreatme...
Autores principales: | Parvin, Parmis, Zola, Marta, Dirani, Ali, Ambresin, Aude, Mantel, Irmela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640735/ https://www.ncbi.nlm.nih.gov/pubmed/28798980 http://dx.doi.org/10.1007/s00417-017-3762-2 |
Ejemplares similares
-
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
por: Marquis, Liza-Marie, et al.
Publicado: (2020) -
MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR–TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen
por: Mantel, Irmela, et al.
Publicado: (2019) -
Refractory neovascular age-related macular degeneration: time-dependent changes of central retinal thickness with anti-VEGF treatment
por: Zola, Marta, et al.
Publicado: (2020) -
Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration
por: Pellegrini, Marco, et al.
Publicado: (2020) -
Final 4-year results of the RAINBOW real-world study: intravitreal aflibercept dosing regimens in France in treatment-naïve patients with neovascular age-related macular degeneration
por: Cohen, Salomon-Yves, et al.
Publicado: (2022)